Revolution Medicines Past Earnings Performance
Past criteria checks 0/6
Revolution Medicines's earnings have been declining at an average annual rate of -39.2%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been declining at an average rate of 12.4% per year.
Key information
-39.2%
Earnings growth rate
52.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -12.4% |
| Return on equity | -23.9% |
| Net Margin | -3,768.3% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity
Apr 12Revolution Medicines Is Hard To Understand
Feb 01Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation
Aug 09
Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates
May 13We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth
Apr 02We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Dec 20We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate
Sep 15Revolution Medicines promotes Jack Anders to CFO
Sep 02New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)
Aug 10Revolution Medicines to raise up to $200M in stock offering
Jul 19Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Slashed This Year's Revenue Estimates By 11%
May 11We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Mar 31Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans
Dec 16What Does The Future Hold For Revolution Medicines, Inc. (NASDAQ:RVMD)? These Analysts Have Been Cutting Their Estimates
Aug 17Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans
Aug 03Revenue & Expenses BreakdownBeta
How Revolution Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 12 | -436 | 62 | 0 |
| 30 Sep 23 | 26 | -331 | 54 | 0 |
| 30 Jun 23 | 30 | -296 | 49 | 0 |
| 31 Mar 23 | 35 | -259 | 45 | 0 |
| 31 Dec 22 | 35 | -249 | 41 | 0 |
| 30 Sep 22 | 30 | -245 | 38 | 0 |
| 30 Jun 22 | 27 | -224 | 36 | 0 |
| 31 Mar 22 | 27 | -208 | 33 | 0 |
| 31 Dec 21 | 29 | -187 | 30 | 0 |
| 30 Sep 21 | 29 | -169 | 28 | 0 |
| 30 Jun 21 | 40 | -143 | 25 | 0 |
| 31 Mar 21 | 42 | -126 | 23 | 0 |
| 31 Dec 20 | 43 | -110 | 21 | 0 |
| 30 Sep 20 | 46 | -95 | 20 | 0 |
| 30 Jun 20 | 46 | -85 | 18 | 0 |
| 31 Mar 20 | 48 | -71 | 15 | 0 |
| 31 Dec 19 | 50 | -62 | 12 | 0 |
| 30 Sep 19 | 48 | -57 | 12 | 0 |
| 31 Dec 18 | 20 | -49 | 9 | 0 |
Quality Earnings: RVMD is currently unprofitable.
Growing Profit Margin: RVMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RVMD is unprofitable, and losses have increased over the past 5 years at a rate of 39.2% per year.
Accelerating Growth: Unable to compare RVMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RVMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: RVMD has a negative Return on Equity (-23.89%), as it is currently unprofitable.